Compare Kimberly Clark Corp (KMB) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Mesoblast Limited — how do they compare? Kimberly Clark Corp trades at $108.57 (market cap $36.11B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: Kimberly Clark Corp is far larger — about 16.3× Mesoblast Limited's market cap, and Kimberly Clark Corp pays a 4.72% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| KMB | MESO | |
|---|---|---|
Market Cap | $36.11B | $2.21B |
Sector | Consumer Staples | Technology |
52-Week High | $134.81 | $20.96 |
52-Week Low | $93.05 | $12.88 |
Enterprise Value | $41.67B | $2.21B |
Dividend Yield | 4.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
